Perceptive Advisors BLTE Position
Active5-Fund ConvergencePerceptive Advisors increased their position in BELITE BIO, INC (BLTE) in Q4 2025, holding $66.3M worth of shares across 414,239 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
BLTE is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Tinlarebant in 440 days (Jun 30, 2027), making the timing of Perceptive's position particularly relevant.
About BELITE BIO, INC
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Full company profile →Short Interest
4.5%
5.6 days to cover
Perceptive Advisors BLTE Position History
Frequently Asked Questions
Does Perceptive Advisors own BLTE?
Yes. As of Q4 2025, Perceptive Advisors holds 414,239 shares of BELITE BIO, INC (BLTE) valued at $66.3M. This data comes from their SEC 13F filing.
How many hedge funds own BLTE?
5 specialist biotech hedge funds currently hold BLTE, including RTW Investments, RA Capital Management, Eventide Asset Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy BLTE?
Perceptive Advisors's position in BLTE was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's BLTE position increasing or decreasing?
Perceptive Advisors increased their BLTE position in the most recent quarter, adding 364,451 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
BLTECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →